Dassault Systèmes is in talks to buy a drug trial software group for about $2 billion, according to the headline. The article body contains only webpage styling code (CSS) and provides no further details about the deal, the target company, or the parties involved. The item is sourced from ft_crypto.
This item was indexed from its published source and tied to the entity records it names. The Counterparty reports what the market says and who it says it about; it does not rewrite the original report. Read the source for the full account.